Mitesco Inc
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Summary of Executive Compensation
Three directors were appointed on December 15, 2023, replacing the previous Board of Directors. They have elected to receive no compensation for 2023.
The following summary compensation table sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the periods ended December 31, 2023 and 2022.
Summary Compensation Table
| Salary · Salary | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| earned · earned · Non-Equity · Nonqualified | ||||||||||
| and · and · Incentive · Deferred · All | ||||||||||
| Name and · paid · unpaid · Stock · Option · Plan · Compensation · Other | ||||||||||
| Principal · in cash · in cash · Bonus · Awards · Awards · Compensation · Earnings · Compensation · Total | ||||||||||
| Position | Year | ($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) | ($) |
| Mack Leath | 2023 | - | - | - | - | - | - | - | - | - |
| Chief Executive Officer and Chief Financial Officer | 2022 | - | - | - | - | - | - | - | - | - |
| Lawrence Diamond | 2023 | 7,000 | 233,385 | - | - | - | - | 634,114(a) | 874,499 | |
| Former Chief Executive Officer | 2022 | 177,885 | 77,460 | - | - | - | - | - | 14,384(b) | 269,729 |
| Thomas Brodmerkel | 2023 | - | 115,385 | - | - | - | - | - | 95,791(a) | 211,176 |
| Former Chief Financial Officer | 2022 | 28,846 | 38,792 | - | - | 23,316(c) | - | - | 6,291(b) | 97,245 |
| Jenny Lindstrom | 2023 | - | 96,154 | - | - | - | - | - | - | 96,154 |
| Former Chief Legal Officer | 2022 | 182,693 | 77,183 | - | - | - | - | - | 14,394(b) | 274,260 |
| Shelia Schweitzer | 2023 | - | 109,231 | - | - | - | - | - | - | 109,231 |
| Former Chief Operating Officer | 2022 | - | - | - | - | - | - | - | - | - |
| Jessica Finnegan | 2023 | 7,000 | 109,827 | - | - | - | - | - | - | 116,827 |
| VP Human Resources | 2022 | 121,777 | 65,007 | - | - | - | - | - | - | 186,784 |
| For "The Good Clinic, LLC" subsidiary | ||||||||||
| Michael Howe | 2023 | 1,000 | 1,349 | - | - | - | - | - | 49,895(a) | 52,244 |
| Former Chief Executive Officer | 2022 | 134,615 | 33,215 | - | - | - | - | - | 8,986(b) | 176,817 |
| Bradley Case | 2023 | 2,000 | 21,077 | - | - | - | - | - | - | 23,077 |
| Former President | 2022 | 138,462 | 59,913 | - | - | - | - | - | 11,659(b) | 210,033 |
| (a) | Consists of an equity incentive for the conversion of notes and accrued compensation into Series F preferred shares |
| (b) | Consists of reimbursement for health insurance and cell phone costs. |
| (c) | Consists of the fair value of 4,000 stock options granted during the period. |
| (d) | Consists of severance pay in the amount of $19,230 and reimbursement for health insurance and cell phone costs in the Amount of $8,130. |
Executive Employment, Termination and Change of Control Arrangements
The Company appointed three (3) new Directors on December 15, 2023. They have elected to receive no compensation for 2023.
They have agreed to serve for one (1) year terms and have agreed to a compensation plan that provides for a) $60,000 per year stipend to be paid by the issuance of Series X Preferred Stock, and b) reimbursement of any real and actual cash expenses incurred in the execution of their responsibilities such as travel, office supplies or similar nominal expenses.
The Series X Preferred shares have a face value of $25 per share and pay dividend of 10% in cash or through the issuance of restricted common stock monthly. All dividends to date for previously issued shares have been paid through the issuance of restricted common stock, and it is anticipated that this practice will continue indefinitely.
For 2024, in conjunction with this award each of the Directors will receive a total of 2,400 shares of Series X Preferred stock. Each share has voting rights entitling it to four hundred (400) votes, when compared to common stock which has one (1) vote per share. As such each director will be entitled to 960,000 share votes on any matter requiring a vote.
Starting in July 2023 and continuing until further notice the Company intends to pay the Series X dividends using restricted common stock with a valuation of $.80 per share, a 20% discount to the average price of the stock before it was moved to the OTC Expert Market Quote platform.
The Certificate of Designation for the Series X Preferred stock (as previously filed in Delaware, and recently converted to Nevada with the same terms) can be viewed here: https://www.sec.gov/Archives/edgar/data/802257/000118518520000019/ex_168535.htm
Officer Compensation
Effective December 15, 2023, the officers of the Company shall not receive any compensation, either accrued or paid.
Pension Benefits; Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans
We do not offer pension benefits, non-qualified contribution, or other deferred compensation plans to our executive officers.
Outstanding Equity Awards at December 31, 2023
The following table shows for the fiscal year ended December 31, 2023, certain information regarding outstanding equity awards at fiscal year-end for the Named Executive Officers. None of the newly elected Named Executive Officers have outstanding equity awards at December 31, 2023.
Note: In January 2024 the Board of Directors terminated the stock option plan, and all previously issued options.
The details can be found here: https://www.sec.gov/ix?doc=/Archives/edgar/data/0000802257/000118518524000060/mitesco20240109_8k.htm
| Securities · Securities | |||||
|---|---|---|---|---|---|
| Underlying · Underlying | |||||
| Unexercised · Unexercised · Options | |||||
| Name and Principal · Options (#) · Options (#) · Exercise · Option | |||||
| Position | Grant Date | Exercisable | Unexercisable | Price ($) | Expiry Date |
| Lawrence Diamond, Former CEO | July 21, 2021 | - | 30,000(a) | $12.50 | July 21, 2031 |
| Thomas Brodmerkel, Former CFO | February 27, 2020 | 11,667 | - | $1.50 | February 27, 2030 |
| December 28, 2020 | 2,000 | - | $1.50 | December 28, 2020 | |
| Jenny Lindstrom, Former Chief Legal Officer | April 12, 2021 | 15,000 | 5,000(a) | $15.50 | March 17, 2031 |
| July 21, 2021 | - | 15,000(a) | $12.50 | July 21, 2031 | |
| Michael Howe, Former Chief Executive Officer, The Good Clinic LLC | June 1, 2021 | 4,000 | 16,000(a) | $13.00 | June 17, 2031 |
| July 21, 2021 | - | 10,000(a) | $12.50 | July 21, 2031 | |
The following table sets forth, for the year ended December 31, 2023, information relating to the compensation of each director who served on our Board of Directors during the fiscal year and who was not a named executive officer. This compensation was for their role as Director of the Company within the fiscal year.
| Fees · Non-Equity · Nonqualified | |||||||
|---|---|---|---|---|---|---|---|
| Earned or · Incentive · Deferred · All | |||||||
| Paid in · Stock · Options · Plan · Compensation · Other | |||||||
| Name and Principal | Cash ($) | Awards | Awards | Compensation | Earnings | Compensation | Total |
| Position | ($) | ($) | ($)(a) | ($) | ($) | ($)(g) | ($) |
| Thomas Brodmerkel (b) | 15,000 | - | - | - | 29,250 | 44,250 | |
| Dr. H. Faraz Naqvi (c) | 7,500 | - | - | - | - | - | 7,500 |
| Juan Carlos Iturregui (e) | 30,000 | - | - | - | 84,073 | 114,073 | |
| Sheila Schweitzer (d) | 15,000 | - | - | - | - | 15,000 | 15,000 |
| Allen Plunk | 15,000 | - | - | - | - | - | 15,000 |
| Mack Leath (f) | - | - | - | - | - | - | - |
| Jordan Balencic (f) | - | - | - | - | - | - | - |
| John Mitch (f) | - | - | - | - | - | - | - |
| (a) | Amount represents the fair value of stock options granted during the period. |
| (b) | Mr. Brodmerkel’s term as Chairman concluded on June 6, 2023. |
| (c) | Effective April 14, 2023, Dr. H. Faraz Naqvi resigned as a director of the Company. |
| (d) | On June 6, 2023, Sheila Schweitzer assumed the position as Chairperson of the Board. Sheila Schweitzer resigned as a director on December 15, 2023 |
| (e) | On December 15, 2023, Juan Carlos Iturregui resigned as a director of the Company. |
| (f) | On December 15, 2023, Mack Leath, Jordan Balencic and John Mitch were elected to the Board of Directors |
| (g) | Amount represents equity incentive benefits related to conversion of accrued compensation and outstanding notes payable |
The table below shows the aggregate number of option awards outstanding at fiscal year-end for each of our current and former non-employee directors.
| Number of | |
|---|---|
| Outstanding Options | |
| Name and Principal | As of |
| Position | December 31, 2023 |
| Thomas Brodmerkel | 22,667 |
| Dr. H. Faraz Naqvi | 4,000 |
| Juan Carlos Iturregui | 3,700 |
| Sheila Schweitzer | 20,700 |
| Mack Leath | - |
| Jordan Balencic | - |
| John Mitch | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.